BAN 2401

Drug Profile

BAN 2401

Alternative Names: BAN-2401

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioArctic Neuroscience
  • Developer BioArctic; Eisai Co Ltd
  • Class Antidementias; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Brain injuries; Down syndrome

Most Recent Events

  • 14 Sep 2017 Preclinical trials in Brain injuries in Sweden (Parenteral) before September 2017 (BioArctic pipeline, September 2017)
  • 14 Sep 2017 Preclinical trials in Down syndrome in Sweden (Parenteral) before September 2017 (BioArctic pipeline, September 2017)
  • 16 Jul 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top